Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 66 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: HIV Lipodystrophy Clear all
Completed Phase 3 Interventional

TH9507 in Patients With HIV-Associated Lipodystrophy

NCT00123253
View directory record Official record
Conditions
HIV Infections, Lipodystrophy
Interventions
TH9507
Drug
Lead sponsor
Theratechnologies
Industry
Eligibility
18 Years to 65 Years
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
35
States / cities
Los Angeles, California • Palm Springs, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2013 · Synced Jul 23, 2026, 2:56 PM EDT
Completed No phase listed Observational

Facial Lipoatrophy Correction Experience With SCULPTRA ("FACES" Study)

NCT00360932
View directory record Official record
Conditions
Facial Lipoatrophy
Interventions
SCULPTRA (poly-L-lactic acid injection)
Device
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Jul 23, 2026, 2:56 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Metabolism and Body Shape of Healthy Children and Children With Chronic Infections

NCT00001142
View directory record Official record
Conditions
HIV Infections, Healthy, Hyperlipidemia, Lipodystrophy
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Not listed
Enrollment
185 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 23, 2026, 2:56 PM EDT
Completed Phase 2 Interventional Results available

Randomized, Placebo-Controlled Study of Leptin for the Treatment of HIV Lipodystrophy and Metabolic Syndrome

NCT00140244
View directory record Official record
Conditions
HAART-induced Lipodystrophy and Metabolic Syndrome
Interventions
r-metHuLeptin, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Jul 23, 2026, 2:56 PM EDT
Completed Not applicable Interventional

Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities

NCT00015691
View directory record Official record
Conditions
HIV Infections, Lipodystrophy, Hyperinsulinemia
Interventions
Metformin hydrochloride, Rosiglitazone maleate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
34
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2013 · Synced Jul 23, 2026, 2:56 PM EDT
Terminated Phase 1 Interventional

Effects of IGF-I in HIV Metabolic Disease

NCT01329744
View directory record Official record
Conditions
HIV Lipodystrophy
Interventions
mecasermin, Placebo control
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 22, 2016 · Synced Jul 23, 2026, 2:56 PM EDT
Not listed Phase 4 Interventional

SHARE: Simple HAART With Abacavir, Reyataz, and Epivir

NCT00426296
View directory record Official record
Conditions
HIV Infections, Lipodystrophy
Interventions
atazanavir (Reyataz), ritonavir (Norvir)
Drug
Lead sponsor
Clinical Alliance for Research & Education - Infectious Diseases, LLC.
Other
Eligibility
18 Years and older
Timeline
Started 2006
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 31, 2007 · Synced Jul 23, 2026, 2:56 PM EDT
Completed No phase listed Observational Results available

Observational Study of Fat Loss in HIV Infected Adults Taking Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

NCT00119405
View directory record Official record
Conditions
HIV Infections, Lipodystrophy, Metabolic Diseases, Nutrition Disorders
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Jul 23, 2026, 2:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Artefill for the Treatment of HIV-associated Facial Lipoatrophy

NCT02009462
View directory record Official record
Conditions
HIV-facial Lipoatrophy
Interventions
Artefill dermal filler
Drug
Lead sponsor
Gerald Pierone, Jr. M.D.
Other
Eligibility
18 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Vero Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Jul 23, 2026, 2:56 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Immune Response to Pneumococcal Vaccination in Aging HIV Positive Adults

NCT03039491
View directory record Official record
Conditions
HIV Lipodystrophy, Aging
Interventions
Pneumococcal polysaccharide vaccine 23 valent, 13 valent conjugated pneumococcal vaccine
Biological
Lead sponsor
Medical University of South Carolina
Other
Eligibility
21 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 15, 2020 · Synced Jul 23, 2026, 2:56 PM EDT
Completed No phase listed Observational

The Cleveland Cardiometabolic Cohort

NCT03059121
View directory record Official record
Conditions
HIV, Lipodystrophy
Interventions
Dual-energy X-ray absorptiometry
Diagnostic Test
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
16 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Jul 23, 2026, 2:56 PM EDT
Withdrawn No phase listed Observational

Egrifta Replacement and Sleep Disordered Breathing

NCT01788462
View directory record Official record
Conditions
Lipodystrophy
Interventions
Tesamorelin (Egrifta)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Jul 23, 2026, 2:56 PM EDT
Completed No phase listed Observational

Perceived Changes in Body Build and Image in Patients Who Are Now Taking or Recently Have Stopped Taking Anti-HIV Drugs

NCT00006290
View directory record Official record
Conditions
HIV Infections, Lipodystrophy
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
San Diego, California • Baltimore, Maryland • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2008 · Synced Jul 23, 2026, 2:56 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome

NCT00362440
View directory record Official record
Conditions
HIV Lipodystrophy
Interventions
Leptin, Pioglitazone or metformin, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Jul 23, 2026, 2:56 PM EDT
Completed Phase 2 Interventional Results available

Rosiglitazone Effect on Mitochondria and Lipoatrophy

NCT00367744
View directory record Official record
Conditions
HIV Infections
Interventions
Rosiglitazone, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 5, 2017 · Synced Jul 23, 2026, 2:56 PM EDT
Completed Phase 4 Interventional

A Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients

NCT00005106
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine/Zidovudine, Abacavir sulfate, Nelfinavir mesylate, Lamivudine, Stavudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
39
States / cities
Birmingham, Alabama • Tucson, Arizona • Longbeach, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 23, 2026, 2:56 PM EDT
Completed Not applicable Interventional

Acipimox to Improve Hyperlipidemia and Insulin Sensitivity Associated With HIV

NCT00246402
View directory record Official record
Conditions
Insulin Resistance, Cardiovascular Diseases, Heart Diseases, HIV Infections, Hypertriglyceridemia, Hyperlipidemia
Interventions
Acipimox
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Jul 23, 2026, 2:56 PM EDT
Completed No phase listed Observational

Growth Hormone Dynamics and Cardiac Steatosis in HIV

NCT03826160
View directory record Official record
Conditions
Human Immunodeficiency Virus, Lipodystrophy, Cardiac Disease
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 70 Years
Enrollment
23 participants
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Jul 23, 2026, 2:56 PM EDT
Completed Not applicable Interventional Results available

HIV Acquired Lipodystrophy (HAL) Classification, Measurement and Fat Response to Thiazolidinedione (TZD) (Pioglitazone)

NCT01023620
View directory record Official record
Conditions
HIV Infections
Interventions
Pioglitazone, Observation
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Jul 23, 2026, 2:56 PM EDT
Completed Not applicable Interventional Results available

Physiologic Growth Hormone Effects in HIV Lipodystrophy

NCT00100698
View directory record Official record
Conditions
AIDS, HIV Infections
Interventions
recombinant human growth hormone, placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2010 · Synced Jul 23, 2026, 2:56 PM EDT
Completed Phase 2 Interventional

Changing to Nonprotease Inhibitor Treatment to Improve Side Effects

NCT00021463
View directory record Official record
Conditions
HIV Infections, Lipodystrophy
Interventions
Abacavir sulfate, Lamivudine and Zidovudine, Abacavir sulfate, Efavirenz, Nevirapine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
11
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2011 · Synced Jul 23, 2026, 2:56 PM EDT
Completed Not applicable Interventional Results available

Diet, Exercise, Niacin, and Fenofibrate to Reduce Heart Disease Risk Factors in Individuals With HIV Lipodystrophy or Dyslipidemia

NCT00246376
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, HIV Infections, Hyperlipidemia, Hypertriglyceridemia, Insulin Resistance, Atherosclerosis
Interventions
Diet, Exercise, Niacin, Fenofibrate, Placebos
Behavioral · Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 20, 2016 · Synced Jul 23, 2026, 2:56 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Effects of a Uridine Supplement on HIV Infected Adults With Lipoatrophy

NCT00307164
View directory record Official record
Conditions
HIV Infections, Lipoatrophy
Interventions
NucleomaxX, NucleomaxX placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
29
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Jul 23, 2026, 2:56 PM EDT
Completed Phase 3 Interventional

Safety and Effectiveness of Fenofibrate and Pravastatin in HIV-Positive Patients With Abnormal Blood Lipids

NCT00006412
View directory record Official record
Conditions
HIV Infections, Lipodystrophy
Interventions
Pravastatin sodium, Fenofibrate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2003
U.S. locations
57
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jul 23, 2026, 2:56 PM EDT